Biosimilars· June 21, 2026 · 6 min read
Enbrel biosimilars compared: FDA approvals, patent litigation, and the 2029 market entry
By Ran Chen#Biosimilars#FDA Approval#TNF Inhibitor
Topic
TNF Inhibitor
TNF blocker access, biosimilar switching, immunology sequencing, and payer preference across inflammatory diseases.
Evidence· June 19, 2026 · 14 min read
TNF inhibitors in FAERS: 1,561,353 adverse-event reports by the numbers
Pricing & Access· June 4, 2026 · 14 min read
TNF inhibitor access landscape: Humira, Enbrel, Remicade, Cimzia, and Simponi in 2026
By Ran Chen#Biosimilars#TNF Inhibitor#Payer Coverage
Biosimilars· May 27, 2026 · 9 min read
Simponi and Simponi Aria biosimilars guide
By Ran Chen#Biosimilars#TNF Inhibitor#Immunology